French study finds nirsevimab may cut infants’ pneumococcal hospitalisations by a third

A large French cohort study reveals that nirsevimab, a long-acting monoclonal antibody used to protect against respiratory syncytial virus, is also associated with a significant reduction in hospital admissions for invasive pneumococcal disease in infants, with effects lasting up to…













